Volume 11, issue 1
Review papers
Neuroleptic malignant syndrome
ST ANLEY N. CAROFF1, STEPHAN C. MANN1, E. CABRINA CAMPBELL1, Stefan Krzymiński2
1. Department of Psychiatry University o f Pennsylvania School of Medicine and the Department ofVeterans Affairs Medical Center, Philadelphia, Pennsylvania, USA
2. Szpitala Specjalistycznego dla Nerwowo i Psychicznie Chorych Samodzielnego Wojewódzkiego Publicznego Zakładu Opieki Zdrowotnej w Ciborzu
Postępy Psychiatrii i Neurologii, 2002, II, 23-30
Keywords: neuroleptic malignant syndrome, diagnostic criteria, treatment
Abstract
Since the initial description ofneuroleptic malignant syndrome (NMS) 40 years ago, a wealth of clinical data has accumulated on the
manifestations, course, treatment and pathogenesis of this uncommon but serious and potentially Zethal drug reaction. Nevertheless vigilance must be maintained, as this disorder remains obscure to many practising physicians. Herc we review the clinical features of NMS to enhance patient safety and reduce physician liability whenever antipsychotic drugs are administered.
Address for correspondence:
Adres: Prof Stanley N. Caroff, M. D., VA Medical Center-116A, University Avenue, Philadelphia,
PA 19104, USA. Dr Stefan Krzymiński, 66-212 Cibórz 3612